biopreparatБИОпрепараты. Профилактика, диагностика, лечениеBiological Products. Prevention, Diagnosis, Treatment2221-996X2619-1156Scientific Centre for Expert Evaluation of Medicinal Productsbiopreparat-30Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESРазработка процесса непрерывного культивирования клеток CHO - продуцентов рекомбинантного фактора свертываемости крови VIIIDevelopment of continuous cultivation of CHO cells producing recombinant blood coagulation factor VIIIМорозовА. Н.MorozovA. N.noemail@neicon.ruСидельниковГ. Д.SidelnikovG. D.noemail@neicon.ruЕмельяновИ. М.EmelyanovI. M.noemail@neicon.ruЛапшинК. Е.LapshinK. E.noemail@neicon.ruАлимоваД. Р.AlimovaD. R.noemail@neicon.ruООО «Международный Биотехнологический Центр «Генериум»РоссияInternational Biotechnological Center «Generium»Russian Federation201520022018042631Copyright © Морозов А.Н., Сидельников Г.Д., Емельянов И.М., Лапшин К.Е., Алимова Д.Р., 20182018Морозов А.Н., Сидельников Г.Д., Емельянов И.М., Лапшин К.Е., Алимова Д.Р.Morozov A.N., Sidelnikov G.D., Emelyanov I.M., Lapshin K.E., Alimova D.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.biopreparations.ru/jour/article/view/30

Проведена разработка процесса перфузионного культивирования продуцента рекомбинантного фактора свертываемости крови VIII, созданного на основе клеток яичников китайского хомячка (СНО). Оптимизирован состав питательной среды, а также температура культивирования продуцента. Осуществлена апробация процесса культивирования в лабораторном биореакторе волнового типа. Показано значительное увеличение выхода активного белка в результате проведенной разработки.

Perfusion cultivation process for CHO cells producing recombinant B-domen deleted coagulation factor VIII was developed. Cell culture medium and feed supplement were optimized by screening of big panel of prototype media and supplements. Cultivation temperature was optimized for better expression of complex protein as well. Cultivation process was tested in a laboratory-scale perfusion bioreactor. Significant increase of productivity was shown as a result of the development.

рекомбинантный фактор свертываемости крови VIIIклетки СНОперфузионное культивированиеоптимизациябиореакторrecombinant coagulation factor VIIICHO cellsperfusion cultivationoptimizationbioreactorReferencesFay P.J. Factor VIII structure and function. Int J Hematol. 2006; 83: 103-8.Fay P.J. Factor VIII structure and function. Int J Hematol. 2006; 83: 103-8.Casademunt E., Martinelle K., Jernberg M., Winge S., Tiemeyer M., Biesert L., et al. The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur J Haematol. 2012; 89(2): 165-76.Casademunt E., Martinelle K., Jernberg M., Winge S., Tiemeyer M., Biesert L., et al. The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur J Haematol. 2012; 89(2): 165-76.Miao H., Sirachainan N., Palmer L., Kucab P., Cunningham M., Kaufman R., Pipe S. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103:3412-9.Miao H., Sirachainan N., Palmer L., Kucab P., Cunningham M., Kaufman R., Pipe S. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103:3412-9.Kaufman R.J., Wasley L.C., Davies M.V., Wise R.J., Israel D.I., Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in chinese hamster ovary cells. Mol Cell Biol. 1988; 9(3): 1233-42.Kaufman R.J., Wasley L.C., Davies M.V., Wise R.J., Israel D.I., Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in chinese hamster ovary cells. Mol Cell Biol. 1988; 9(3): 1233-42.Adamson R. Design and operation of a recombinant mammalian cell manufacturing process for rFVIII. Ann Hematol. 1994; 68:9-14.Adamson R. Design and operation of a recombinant mammalian cell manufacturing process for rFVIII. Ann Hematol. 1994; 68:9-14.Clincke M., Molleryd C., Zhang Y., Lindskog E., Walsh K., Chotteau V. Very high cell dencity of CHO cells in perfusion by ATF or TFF in WAVE bioreactor. Part I. Effect of the cell dencity on the process. Biotechnol Prog. 2013; 29(3): 754-67.Clincke M., Molleryd C., Zhang Y., Lindskog E., Walsh K., Chotteau V. Very high cell dencity of CHO cells in perfusion by ATF or TFF in WAVE bioreactor. Part I. Effect of the cell dencity on the process. Biotechnol Prog. 2013; 29(3): 754-67.Santagostino E. A new recombinant factor VIII: from genetics to clinical use. Drug Des Devel Ther. 2014; 8:2507-15.Santagostino E. A new recombinant factor VIII: from genetics to clinical use. Drug Des Devel Ther. 2014; 8:2507-15.Kaufman R.J. Insight into the structure., function., and biosynthesis of factor VIII through recombinant DNA technology. Ann Hematol. 1991; 63(3): 155-65.Kaufman R.J. Insight into the structure., function., and biosynthesis of factor VIII through recombinant DNA technology. Ann Hematol. 1991; 63(3): 155-65.Ezban M., Vad K., Kjalke M. Turoctocog alfa (NovoEight) - from design to clinical proof of concept. Eur J Haematol. 2014; 93(5): 369-76.Ezban M., Vad K., Kjalke M. Turoctocog alfa (NovoEight) - from design to clinical proof of concept. Eur J Haematol. 2014; 93(5): 369-76.Chotteau V., Bjorling T., Boork S., Brink-Nilsson H. Development of a large scale process for the production of recombinant truncated factor VIII in CHO cells under cell growth arrest conditions. In: Lindner-Olsson E. Animal Cell Technology: From Target to Market. Kluwer Academic Publ.; 2001. P. 287-91.Chotteau V., Bjorling T., Boork S., Brink-Nilsson H. Development of a large scale process for the production of recombinant truncated factor VIII in CHO cells under cell growth arrest conditions. In: Lindner-Olsson E. Animal Cell Technology: From Target to Market. Kluwer Academic Publ.; 2001. P. 287-91.Chuppa S., Tsai Y., Yoon S., Shackleford S., Rozales C., Bhat R., et al. Fermentor temperature as a tool for control of high-dencity perfusion cultures of mammalian cells. Biotechnol Bioeng. 1997; 55(2): 328-38.Chuppa S., Tsai Y., Yoon S., Shackleford S., Rozales C., Bhat R., et al. Fermentor temperature as a tool for control of high-dencity perfusion cultures of mammalian cells. Biotechnol Bioeng. 1997; 55(2): 328-38.Genzel Y., Vogel T., Buck J., Behrendt I., Ramirez D.V., Schiedner G., et al. High cell dencity cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells. Vaccine 2014; 32(24): 2770-81.Genzel Y., Vogel T., Buck J., Behrendt I., Ramirez D.V., Schiedner G., et al. High cell dencity cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells. Vaccine 2014; 32(24): 2770-81.Kolind M.P., Norby P.L., Flintegaard T.V., Berchtold M.W., Johnsen L.B. The B-domain of Factor VIII reduces cell membrane attachment to host cells under serum free conditions. J Biotechnol. 2010; 147(3-4): 198-204.Kolind M.P., Norby P.L., Flintegaard T.V., Berchtold M.W., Johnsen L.B. The B-domain of Factor VIII reduces cell membrane attachment to host cells under serum free conditions. J Biotechnol. 2010; 147(3-4): 198-204.Rasmussen P.B. Method of producing proteins with FVIII activity and/or FVIII derivatives. Patent WO., № 1991000347 A1; 1991.Rasmussen P.B. Method of producing proteins with FVIII activity and/or FVIII derivatives. Patent WO., № 1991000347 A1; 1991.

The authors declare that there are no conflicts of interest present.